Meningeome

The prognosis of the generally benign meningiomas is mainly an issue of the likelihood of recurrence, which increases with WHO grade ( 7-20% in WHO grade I, 29-40% in WHO grade II, and 50-78% in WHO grade III meningiomas). Among clinical parameters the most important prognostic factor is the completeness of neurosurgical tumor resection. Among histopathological prognostic parameters the mitotic activity is the most important one. As the cutoffs of the mitotic index (MI) are defined for each grade by the WHO classification of brain tumors and because the MI can be applied as the sole grading criterion, the reliable and reproducible assessment of the MI is crucial for an appropriate risk stratification. This is provided by immunohistochemical mitosis markers, i.e., phospho-histone H3 (PHH3). The PHH3 method is superior to the conventional mitosis counting method and therefore allows a more reliable risk stratification. The Ki-67 labeling index provides additional prognostic information, especially in prognostically ambiguous meningiomas. Cytogenetically, the deletion of the short arm of one chromosome 1 (1p-) is an unfavorable prognostic parameter and is correlated with a high risk of recurrence. The enzyme reaction for alkaline phosphatase ( ALPL) is a fast and efficient screening method, which strongly indicates an intact chromosome 1 in cases with a positive enzyme reaction.